^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Proton pump inhibitor

    Related drugs:
    3d
    Gastroprotective effect of Kahweol against ethanol-induced gastric ulcer by employing in silico, in vitro and in vivo approaches. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    This is the first study demonstrating the multifaceted gastroprotective effects of Kahweol using an integrated computational, in vitro, and in vivo approaches, including direct comparison with omeprazole and evidence of dual acid-suppressive and anti-H...These findings suggest Kahweol is the potential natural agent for the prevention and treatment of ethanol-induced GU, highlighting the comprehensive gastroprotective effects of Kahweol through its antioxidant, anti-inflammatory, anti-secretory, and anti-H. pylori activity.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta) • CAT (Catalase)
    |
    omeprazole
    6d
    The Efficacy and Safety of Anaprazole Quadruple Therapy Versus Rabeprazole Quadruple Therapy for Helicobacter pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study (ChiCTR2600117235)
    P=N/A, N=220, Not yet recruiting, NanJing First Hospital; NanJing First Hospital
    New trial
    6d
    Efficacy and Safety of Keverprazan-Amoxicillin Dual Therapy Versus Bismuth-Containing Quadruple Therapy as Rescue Treatment for Helicobacter Pylori Infection: A Prospective Multicenter Randomized Controlled Trial (ChiCTR2600116788)
    P=N/A, N=180, Not yet recruiting, Northern Jiangsu People's Hospital; Northern Jiangsu People's Hospital
    New trial
    6d
    Efficacy and Safety of Tegoprazan in Continuous Maintenance versus On-Demand Therapy for Patients with Non-Erosive Reflux Disease and Mild Esophagitis: A Prospective, Multicenter, Randomized, Controlled Clinical Study (ChiCTR2500112625)
    P=N/A, N=128, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University; The First Affiliated Hospital with Nanjing Medical University
    New trial
    6d
    Evaluation of the Efficacy and Safety of Keverprazan Hydrochloride in the Treatment of NSAIDs Associated Gastric Ulcers: A Single-Center, Randomized Controlled Clinical Trial Protocol (ChiCTR2500114194)
    P4, N=308, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New P4 trial
    10d
    A novel extracellular vesicle-engineered immunotherapy drug for Her2+ breast cancer. (PubMed, J Adv Res)
    Trastuzumab profoundly improves outcomes of Her2+ breast cancer (BC) patients, but eventual drug resistance is inevitable...Moreover, EVs/Her2-scFv loaded with rabeprazole (EVs/Her2-scFv/Rabe) effectively improve tumor immunosuppressive microenvironment and abnormal vasculature of Her2+ BC by reducing tumor EVs...Besides, EVs/Her2-scFv/CXCL9/Rabe are low-immunogenic with biosafety. Altogether, EVs/Her2-scFv/CXCL9/Rabe hold high potential in Her2+ BC therapy.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD8 (cluster of differentiation 8) • CXCL9 (Chemokine (C-X-C motif) ligand 9)
    |
    Herceptin (trastuzumab)
    14d
    A Trial of Omeprazole and Low Dose Aspirin to Identify Colorectal Biomarkers of Preventive Efficacy (clinicaltrials.gov)
    P1, N=24, Recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Jun 2026 --> Sep 2026 | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    omeprazole
    21d
    A Study of the Pharmacokinetics and Safety of Anaprazole Sodium in Special Populations (clinicaltrials.gov)
    P4, N=60, Not yet recruiting, Xuanzhu Biopharmaceutical Co., Ltd.
    New P4 trial
    22d
    Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication (clinicaltrials.gov)
    P=N/A, N=390, Recruiting, Kaohsiung Medical University | N=780 --> 390
    Enrollment change
    23d
    Yiwei Jiaohuang Ointment for Gastrointestinal Bleeding Associated With Oral Antithrombotic Agents: A Randomized Controlled Trial (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, China-Japan Friendship Hospital
    New P1 trial
    24d
    Efficacy and Safety of Aspirin and Lansoprazole for Prevention of Preterm Birth in High-Risk Pregnant Women: A Biomarker-Enriched Trial (clinicaltrials.gov)
    P2/3, N=670, Not yet recruiting, Stanford University
    New P2/3 trial
    |
    aspirin
    27d
    Targeting fatty acid synthase for cancer drug discovery: Retrospective analyses and outlook. (PubMed, Pharmacol Rev)
    Despite these efforts, only a handful of inhibitors have entered clinical trials, such as 3-V Biosciences-2640 (denifanstat) and repurposed omeprazole, and none have received regulatory approval to date. Despite progress with novel and repurposed inhibitors, none have gained approval. This review critically examines past efforts, current challenges, and offers insights to guide future development of effective fatty acid synthase-targeting cancer therapeutics.
    Retrospective data • Review • Journal
    |
    FASN (Fatty acid synthase)
    |
    denifanstat (TVB-2640) • omeprazole